Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. filed 10 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 2 reporting owners, covering 23 transactions and 250,949 shares. None carries the SEC's AFF10B5ONE flag; all 10 name a plan in a footnote. 8 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2026-06-17, came 91 days after the one before it (2026-03-18) and reports 3 transactions against 3 in the filing before it.
- The sales it reports total 13,314 shares, 17,753 fewer than the 31,067 in the filing before it.
- Its 10 plan statements rank 8th of the 10 companies the register carries in California, its state of incorporation.
- Of the 10 companies the register lists beside it in its industry, 5 have more plan statements on file than it and 5 have fewer.
- Its 10 filings on file run from 2025-01-23 to 2026-06-17, and state one plan adoption date, 2024-03-14.
Trades in Theravance Biopharma, Inc. 23
- Farnum Rhonda — 2025-01-21 · S · 4,000 shares
- Farnum Rhonda — 2025-04-21 · S · 4,000 shares
- Farnum Rhonda — 2025-06-02 · S · 24,000 shares
- Farnum Rhonda — 2025-07-14 · S · 682 shares
- Farnum Rhonda — 2025-07-14 · S · 5,318 shares
- Farnum Rhonda — 2025-07-14 · S · 4,000 shares
- BROSHY ERAN — 2025-11-11 · S · 29,500 shares
- BROSHY ERAN — 2025-11-11 · S · 15,500 shares
- BROSHY ERAN — 2025-11-11 · S · 14,000 shares
- BROSHY ERAN — 2025-11-11 · S · 15,500 shares
- BROSHY ERAN — 2025-11-11 · S · 15,500 shares
- BROSHY ERAN — 2025-11-11 · S · 14,000 shares
Adoption dates in Theravance Biopharma, Inc. 1
- 2024-03-14 — stated in 3 filings
Results prints in Theravance Biopharma, Inc. 8
- 2025-02-26
- 2025-05-08
- 2025-08-12
- 2025-11-10
- 2026-03-03
- 2026-03-19
- 2026-05-07
- 2026-08-10
Trades before a print in Theravance Biopharma, Inc. 3
- 3 days before the 2026-03-19 print — 2026-03-16 · S · Farnum Rhonda · 7,767 shares
- 3 days before the 2026-03-19 print — 2026-03-16 · S · Farnum Rhonda · 15,534 shares
- 3 days before the 2026-03-19 print — 2026-03-16 · S · Farnum Rhonda · 7,766 shares
- 17 days before the 2025-05-08 print — 2025-04-21 · S · Farnum Rhonda · 4,000 shares
- 29 days before the 2025-08-12 print — 2025-07-14 · S · Farnum Rhonda · 682 shares
- 29 days before the 2025-08-12 print — 2025-07-14 · S · Farnum Rhonda · 5,318 shares
- 29 days before the 2025-08-12 print — 2025-07-14 · S · Farnum Rhonda · 4,000 shares
- 36 days before the 2025-02-26 print — 2025-01-21 · S · Farnum Rhonda · 4,000 shares
- 56 days before the 2026-08-10 print — 2026-06-15 · S · Farnum Rhonda · 3,329 shares
- 56 days before the 2026-08-10 print — 2026-06-15 · S · Farnum Rhonda · 3,328 shares
- 56 days before the 2026-08-10 print — 2026-06-15 · S · Farnum Rhonda · 6,657 shares
- 71 days before the 2025-08-12 print — 2025-06-02 · S · Farnum Rhonda · 24,000 shares
Interval to Theravance Biopharma, Inc.’s next reported results date
How the interval and sources are counted →
- 3within 5 days
- 3within 10 days
- 3shortest, days
- 0no later print
- Farnum Rhonda 2026-03-16 · S · 3 days before the 2026-03-19 print · SVP, COMM & MEDICAL AFFAIRS
- Farnum Rhonda 2026-03-16 · S · 3 days before the 2026-03-19 print · SVP, COMM & MEDICAL AFFAIRS
- Farnum Rhonda 2026-03-16 · S · 3 days before the 2026-03-19 print · SVP, COMM & MEDICAL AFFAIRS
Adoption dates Theravance Biopharma, Inc. states
- 2024-03-14 in 3 filings
Filing text: “10b5-1 trading plan adopted on March 14, 2024”
Reported results dates on file
- 2025-02-26
- 2025-05-08
- 2025-08-12
- 2025-11-10
- 2026-03-03
- 2026-03-19
- 2026-05-07
- 2026-08-10
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.
The address of this record
Theravance Biopharma, Inc.’s insider trading plan record — 10 Form 4 statements in the 2025 filing year — is published at one address, this page. When you cite or link the record, use https://velarionrecords.com/plan10b5/issuer/0001583107.